Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017

  • ID: 4433867
  • Report
  • 349 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Array BioPharma Inc
  • Calithera Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Pharma Mar SA
  • MORE
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 16, 14, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Array BioPharma Inc
  • Calithera Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Pharma Mar SA
  • MORE
Introduction

Gastrointestinal Stromal Tumor (GIST) - Overview

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development

AB Science SA

Advanced Accelerator Applications SA

Ariad Pharmaceuticals Inc

Arog Pharmaceuticals Inc

ArQule Inc

Array BioPharma Inc

Ascentage Pharma Group Corp Ltd

Astex Pharmaceuticals Inc

Blueprint Medicines Corp

Boston Biomedical Inc

Calithera Biosciences Inc

Celldex Therapeutics Inc

Chipscreen Biosciences Ltd

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

Hanmi Pharmaceuticals Co Ltd

Horizon Pharma Plc

Immunicum AB

Jiangsu Hengrui Medicine Co Ltd

Loxo Oncology Inc

Merck & Co Inc

Natco Pharma Ltd

Nerviano Medical Sciences Srl

Novartis AG

Omeros Corp

Pharma Mar SA

Plexxikon Inc

Rhizen Pharmaceuticals SA

Taiho Pharmaceutical Co Ltd

Xencor Inc

Gastrointestinal Stromal Tumor (GIST) - Drug Profiles

aldoxorubicin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amcasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anagrelide hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APG-1351 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

binimetinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buparlisib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-839 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-0158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHMFLKIT-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenigacestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenolanib besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-2164 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCC-2618 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-95573 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilixadencel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon gamma-1b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larotrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miransertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRCAN-019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onalespib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

R&D Progress

Peptide to Antagonize GRPR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexidartinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-9486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PM-184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ponatinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-1126 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-1020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-116 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

umbralisib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vemurafenib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WBZ-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-18087 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects

Gastrointestinal Stromal Tumor (GIST) - Discontinued Products

Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones

Featured News & Press Releases

Nov 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFR alpha Genotypes

Nov 10, 2017: Deciphera Pharmaceuticals Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society

Nov 01, 2017: Blueprint Medicines Announces Publication of BLU-285 Translational Data

Sep 11, 2017: Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress

Aug 31, 2017: Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress

Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285

Jun 05, 2017: Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation

Jun 05, 2017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting

May 18, 2017: Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting

May 17, 2017: Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting

Apr 03, 2017: Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations

Nov 30, 2016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors

Nov 30, 2016: Results from 3 ground-breaking studies show early benefit to patients

Nov 16, 2016: Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene

Nov 15, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Co, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Loxo Oncology Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Merck & Co Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Xencor Inc, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • Advanced Accelerator Applications SA
  • Ariad Pharmaceuticals Inc
  • Arog Pharmaceuticals Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Ascentage Pharma Group Corp Ltd
  • Astex Pharmaceuticals Inc
  • Blueprint Medicines Corp
  • Boston Biomedical Inc
  • Calithera Biosciences Inc
  • Celldex Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • Deciphera Pharmaceuticals LLC
  • Eli Lilly and Co
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Horizon Pharma Plc
  • Immunicum AB
  • Jiangsu Hengrui Medicine Co Ltd
  • Loxo Oncology Inc
  • Merck & Co Inc
  • Natco Pharma Ltd
  • Nerviano Medical Sciences Srl
  • Novartis AG
  • Omeros Corp
  • Pharma Mar SA
  • Plexxikon Inc
  • Rhizen Pharmaceuticals SA
  • Taiho Pharmaceutical Co Ltd
  • Xencor Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll